7 active not recruiting, 6 completed, 3 recruiting, 1 enrolling by invitation. 10 Phase 2, 6 Phase 1, 2 Phase 3, 1 Not applicable.
Follow Plexiform Neurofibroma: new trials by email Literature Review of Plexiform Neurofibroma trials Research Report on Plexiform Neurofibroma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas Cabozantinib Oral Tablet, Selumetinib Oral Capsule - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 | Recruiting | Girish Dhall, MD | 30 | 2026-06-09 | 2026-10-02 |
| Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas TQ-B3234 capsules, TQ-B3234 placebo - Plexiform Neurofibroma | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 177 | 2026-03-31 | 2026-05-27 |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 Selumetinib - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 2 | Recruiting | University of Alabama at Birmingham | 200 | 2025-08-27 | 2026-05-29 |
| Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 Luvometinib Tablets - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 65 | 2025-06-12 | 2025-06-17 |
| Neurofibromatosis Type 1 Tumor Early Detection Study Liquid biopsy for MPNST development - Neurofibromatosis Type 1, Neurofibromatosis 1 | Enrolling by invitation | David Miller | 1000 | 2024-08-07 | 2026-08-31 | |
| A Study of Avutometinib for People With Solid Tumor Cancers Avutometinib - Refractory Cancer, CNS Tumors | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 3 | 2023-10-20 | 2026-06-15 |
| FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group (Group B): Placebo, orally, once daily; - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 3 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 167 | 2023-06-20 | 2025-03-06 |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 FCN-159 - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 160 | 2021-03-26 | 2024-11-12 |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Mirdametinib (PD-0325901) oral capsule or dispersible tablet - Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) | Phase 2 | Active not recruiting | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 114 | 2019-09-29 | 2026-10-06 |
| Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Selumetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 14 | 2019-09-26 | 2024-04-04 |
| A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) This study is purely descriptive study. - Neurofibromatosis 1, Plexiform Neurofibroma | Unknown | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2000 | 2019-01-01 | 2024-04-23 | |
| Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. Trametinib - Low-grade Glioma, Plexiform Neurofibroma | Phase 2 | Active not recruiting | St. Justine's Hospital | 114 | 2018-08-16 | 2026-04-24 |
| Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 Whole Body MRI - Neurofibromatosis 1, Neurofibroma | Not applicable | Active not recruiting | Children's National Research Institute | 10 | 2018-07-12 | 2021-03-02 |
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Binimetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 2 | Completed | University of Alabama at Birmingham | 45 | 2017-11-28 | 2025-05-02 |
| PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) Neurofibromatosis-1, Optic Glioma | Completed | UNC Lineberger Comprehensive Cancer Center | 30 | 2013-01-16 | 2021-05-12 | |
| Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas RAD001: Everolimus - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2011-04-01 | 2014-11-14 |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Nexavar (BAY 43-9006) (Sorafenib), Toxicity, Pharmacokinetics, Pharmacodynamics - Neurofibromatosis Type I, Plexiform Neurofibroma | Phase 1 | Completed | National Cancer Institute (NCI) | 9 | 2008-07-08 | 2019-12-12 |
| Natural History Study of Patients With Neurofibromatosis Type I Neurofibromatosis Type 1, Malignant Peripheral Nerve Sheath Tumor | Active not recruiting | National Cancer Institute (NCI) | 259 | 2008-02-25 | 2026-10-16 | |
| Study of PEG-Intron for Plexiform Neurofibromas PEG-Intron - Plexiform Neurofibroma | Phase 2 | Completed | University of Pittsburgh | 86 | 2006-12-01 | 2017-11-06 |
| AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine Cediranib Maleate - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 2 | Terminated | National Cancer Institute (NCI) | 26 | 2006-05-01 | 2017-08-18 |
Neurofibroma, Plexiform (20) · Neurofibromatosis 1 (16) · Neurofibroma (4) · Neurofibromatoses (3) · Optic Nerve Glioma (3) · Brain Neoplasms (2) · Neurofibrosarcoma (2) · Central Nervous System Neoplasms (1) · Glioma (1) · Neoplasms (1) · Neuroblastoma (1) · Neurofibromatosis, type 4, of Riccardi (1) · Peripheral Nervous System Neoplasms (1)
Neoplasms by Histologic Type (20) · Neoplasms, Nerve Tissue (20) · Nerve Sheath Neoplasms (20) · Nervous System Diseases (20) · Nervous System Neoplasms (20) · Neuromuscular Diseases (20) · Peripheral Nervous System Diseases (20) · Neoplasms (19) · Peripheral Nervous System Neoplasms (19) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16) · Genetic Diseases, Inborn (16) · Heredodegenerative Disorders, Nervous System (16) · Neoplastic Syndromes, Hereditary (16) · Neurocutaneous Syndromes (16) · Neurodegenerative Diseases (16)
AZD 6244 (3) · Control Groups (1) · Liquid Biopsy (1) · Pharmacokinetics (1) · Sorafenib (1) · binimetinib (1) · cabozantinib (1) · cediranib (1) · mirdametinib (1) · peginterferon alfa-2b (1) · trametinib (1)
National Cancer Institute (NCI) (3) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (3) · University of Alabama at Birmingham (2) · Assistance Publique - Hôpitaux de Paris (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Children's National Research Institute (1) · David Miller (1) · Girish Dhall, MD (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Memorial Sloan Kettering Cancer Center (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) · St. Justine's Hospital (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Pittsburgh (1)
United States (13) · China (5) · Canada (1) · France (1) · Spain (1) · United Kingdom (1)
Brigitte C Widemann, M.D. (2) · Bruce Korf, MD, PhD (1) · Darren Hargrave, MB Bch (1) · David T Miller, MD, PhD (1) · Dusica Babovic-Vuksanovic (1) · Girish Dhall, MD (1) · Jean Tersak, M.D. (1) · Miriam Bornhorst, MD (1) · Pierre Wolkenstein, MD, PhD (1) · Sameer Farouk Sait, MD (1) · Timothy Gershon, MD, PhD (1) · Wenbin Li, MD (1)
PMID 24321536, PMID 27510726, PMID 30339775, PMID 31881853, PMID 32152628, PMID 35007270, PMID 37400844, PMID 39418437, PMID 39514826, PMID 41139346
N01CM17104 (1), N01CM62205 (1), P30CA015083 (1)